Yongting Wang
Head of Biology, Cell & Gene Therapy Research Astellas Pharma
As Head of Biology in Cell & Gene Therapy Research at Astellas Pharma, I lead efforts in strategic pipeline development and preclinical proof-of-concept studies. My work focuses on leveraging the biology team’s expertise in cell therapy, AAV, aptamer, and mRNA-LNP modalities to advance assets in ophthalmology and CNS diseases.
Collaborating across translational medicine, early development, medical development, regulatory affairs, and commercial teams, I aim to generate mechanistic insights and deliver improved outcomes for patients. My commitment lies in fostering innovation and translating cutting-edge research into impactful therapies.
Seminars
Wednesday 9th September 2026
Advancing iPSC-Derived Ocular Cell Therapies to Improve Vision Restoration & Support Progression into Pivotal Trials
3:40 pm
- Reviewing pipelines with iPSC-derived retinal cell replacement, focusing on preclinical engraftment, structural preservation, and early clinical functional readouts
- Defining meaningful visual endpoints, durability markers and safety criteria that demonstrate clinical benefit and support the move from early-phase studies toward larger efficacy trials
